1993 – Approved by the U.S. Food & Drug Administration

Announcement Date: January 1, 1993

 

Risperdal approved as an atypical antipsychotic by the U.S. Food & Drug Administration (FDA) for the treatment of manic or mixed delusional episodes such as schizophrenia. It soon becomes one of the best-selling and widely-prescribed prescription medications in America.